



CareDx Launches Olerup QTYPE® at ASHI

BRISBANE, Calif., September 28, 2016 (GLOBE NEWSWIRE) – CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced the launch of Olerup QTYPE® at the 42nd Annual Meeting of the American Society of Histocompatibility and Immunogenetics (ASHI) in St. Louis, MO.

During a lunchtime symposium on the pre-to-post transplant continuum, John Lunz, PhD, from the Gift of Hope Organ and Tissue Donor Network discussed the center’s experience with enhanced resolution in rapid HLA typing of deceased donors. Daniel Brennan, MD from the Washington University at St. Louis spoke about post transplant recipients and immunological guidelines. Rapid and precise HLA typing is key in transplantation.

Olerup QTYPE is a robust and easy to use alternative for rapid HLA typing within one hour. This new test brings several needed features to HLA labs, including speed and precision.

Olerup QTYPE is currently for use on the Roche LightCycler 480II, a robust and well established RT-PCR instrument. Validation studies are also underway for the use of Olerup QTYPE on the ABI suite of instruments. Multiple product demonstrations have been scheduled at several HLA laboratories across the US and Europe.

Olerup QTYPE is the first product to launch following the acquisition of Allenex by CareDx. “ASHI provides a unique platform for the company to showcase our pre-to-post transplant strategy,” stated Peter Maag, President and CEO of CareDx. “This new product allows us to build on our expertise and leadership across transplantation.”

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap[®], a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure[®], a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA (dd-cfDNA) after transplantation.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP[®] is a set of HLA typing tools used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. Olerup QTYPE[®] offers speed and precision in real time as a rapid HLA typing tool. XM-ONE[®] is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.caredx.com.

Media Contact

Gordon Hill, CareDx, Inc.
T: +1 267 235 8001
ghill@caredx.com

Investor Contact

Jamar Ismail, Westwicke Partners
T: +1 415-513-1282
jamar.ismail@westwicke.com

Forward Looking Statements

In addition to historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 filed by us with the SEC on August 22, 2016, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.